More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: The randomized head-to-head bright trial

Diabetes Care

Volumn 41, Issue 10, 2018, Pages 2147-2154

  Rosenstock, Julio ^a   Cheng, Alice ^b   Ritzel, Robert ^c   Bosnyak, Zsolt ^d   Devisme, Christine ^e   Cali, Anna M G ^f   Sieber, Jochen ^g   Stella, Peter ^h   Wang, Xiangling ⁱ   Frías, Juan P ^j   Roussel, Ronan ^k,l,m   Bolli, Geremia B ⁿ  

^a Dallas Diabetes and Endocrine Center at Medical City   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Klinikum Schwabing   (Germany)

^d SANOFI   (France)

^e Aixial   (France)

^f National Research Institute ^*  (Japan)

^g Process Development Biotechnology   (Germany)

^h Sanofi   (Hungary)

ⁱ Sorbonne Paris Cité ^*  (China)

^j NATIONAL RESEARCH INSTITUTE   (United States)

^k BICHAT HOSPITAL   (France)

^l CENTRE DE RECHERCHE DES CORDELIERS   (France)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; BODY WEIGHT GAIN; COLON ADENOCARCINOMA; CONFERENCE PAPER; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FASTING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF MONITORING; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALYSIS; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 85055526695     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0559     Document Type: Conference Paper

References (18)

1. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017;19:3-12
2. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
3. 21. Diabetes Care 2015;38:637-643
4. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14: 944-950
5. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14:859-864
6. Ratner RE, Gough SC, Mathieu C, et al. Hypo-glycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175-184
7. Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859-867
8. Bailey TS, Pettus J, Roussel R, et al. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. Diabetes Metab 2018;44:15-21
9. Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab 2017;19:1032-1039
10. Bailey T, Dahmen R, Pettus J, et al. Insulin glargine 300 U/ml (Gla-300) provides more stable and more evenly distributed steady-state pharmacodynamic/pharmacokinetic profiles compared with insulin degludec in type 1 diabetes (T1DM). Endocr Pract 2016;23:48A
11. Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open 2016;6: e009421
12. Bolli GB, Riddle MC, Bergenstal RM, et al.; EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-394
13. Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300 U/ml vs glargine 100 U/ml in T2DM. Diabetes Metab. 19 February 2018 [Epub ahead of print]. DOI: 10.1016/j.diabet. 2018.02.002
14. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581
15. Zinman B, Philis-Tsimikas A, Cariou B, et al.; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35: 2464-2471
16. Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new in-sulinglargine300U/mlhasthesamemetabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-876
17. Scholtz HE, Pretorius SG, Wessels DH, Venter C, Potgieter MA, Becker RH. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion. Acta Diabetol 2003;40: 156-162
18. Werner U, Korn M, Tennagels N. Insulin glargine 300 U/mL and insulin glargine 100 U/mL show equipotent in vivo blood glucose lowering when administered intravenously in dogs (Abstract). Diabetes Technol Ther 2016; 18:A-119